Vaccination with enfortumab vedotin-treated tumor cells results in protection against tumor rechallenge in mice, consistent with antitumor immunity, and MMAE-mediated ICD induction modulates the tumor microenvironment in a complementary manner to immune checkpoint inhibition.
Abstract
Summary Enfortumab vedotin is a Nectin-4-directed antibody-drug conjugate designed to deliver the microtubule-disrupting agent monomethyl auristatin E (MMAE) to tumor cells. Using preclinical models of urothelial cancer (UC), we expand the understanding of the multifaceted mechanism of action for enfortumab vedotin that includes direct cytotoxicity on Nectin-4-positive tumor cells, indirect bystander effect on neighboring Nectin-4-negative tumor cells, and MMAE-mediated induction of immunogenic cell death (ICD) and associated increase in activated immune cells in the tumor microenvironment. Importantly, vaccination with enfortumab vedotin-treated tumor cells results in protection against tumor rechallenge in mice, consistent with antitumor immunity. MMAE-mediated ICD induction modulates the tumor microenvironment in a complementary manner to immune checkpoint inhibition. Accordingly, enfortumab vedotin plus PD-1 inhibitor shows enhanced antitumor activity in vivo. These preclinical findings provide mechanistic hypotheses that may be relevant to the improved clinical outcomes observed for enfortumab vedotin plus pembrolizumab relative to chemotherapy.
Findings delineate a ferroptosis–ICD–immune axis underlying the antitumor activity of RC48 and support its clinical development as a monotherapy or in combination with immune checkpoint inhibitors for HER2-expressing breast cancer.
Ying-Ying Zhao, Chen-Wei Yuan, Qiong Wu et al.· Journal of Experimental &...· 0 citations
It is found that PLK4 was up-regulated in DLBCL, and its silencing significantly inhibited tumor growth, and the combination of si-PLK4 and VCR exerted stronger anti-tumor effects than either treatment alone, which was mediated by activating cGAS-STING pathway.
Zuofei Chi, Nan-Nan Xu, Ying Sun et al.· Cancer Letters· 0 citations
The multi-RAS inhibitor, daraxonrasib, has demonstrated a remarkable improvement in outcomes for patients with metastatic PDAC. Pre-clinical murine studies have shown that the durable effects of the pre-clinical multi-RAS inhibitor, RMC-7977, require an intact immune system including CD8+ T cells and cross-presen...
Sheela R. Damle, Nancy Liu, Xiu-Yun Jiang et al.· Cancer Research· 0 citations
Immune checkpoint inhibitors (ICIs) have improved cancer outcomes; however, many patients fail to respond, highlighting the need for novel targets. HVEM (Herpes Virus Entry Mediator) is an immune regulator with both inhibitory and stimulatory functions, making it a promising therapeutic candidate. We have developed Ant...
Gilli Galore-Haskel, Efrat Merhavi-Shoham, M. Shapiro et al.· Molecular Cancer Therapeutic...· 1 citation
Disulfiram (DSF) is an FDA-approved drug with pleiotropic anticancer activity, including induction of cellular stress and effects on stemness-associated phenotypes in ovarian cancer. Here, we investigated whether DSF enhances the antitumor efficacy of the CHK1 inhibitor MK-8776 in ovarian cancer models, with emphasis...
Wiktoria Bębenek, A. Gajek, A. Rogalska· Scientific Reports· 0 citations
Findings establish anwulignan as a dual-function therapeutic that directly targets MM cell survival while simultaneously promoting anti-tumor immunity through pyroptosis-driven immunogenic cell death.
Xin-Yun Zhang, Zhi-Ming Wang, Yi-Lei Shi et al.· Apoptosis· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.